NRx Pharmaceuticals, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing NMDA-receptor therapies for suicidal depression, bipolar depression, chronic pain, PTSD, schizophrenia and resistant infections. Its subsidiaries include NeuroRx, focused on research and development, and HOPE Therapeutics, focused on ketamine-related specialty pharmaceutical and care-delivery activities. The filing covers the three months ended March 31, 2024; financial statements are unaudited and presented in thousands except per-share and share data.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| Revenue | $0; no revenue has been generated | $0 |
| Research and development expense | $1.748 million | $3.650 million |
| General and administrative expense | $4.250 million | $5.785 million |
| Total operating expenses | $5.998 million | $9.435 million |
| Loss from operations | $5.998 million | $9.435 million |
| Net loss | $6.528 million, or $0.74 per share | $11.039 million, or $1.66 per share |
| Operating cash flow | $(3.671) million | $(6.089) million |
| Cash and cash equivalents at period end | $1.319 million | $4.595 million at December 31, 2023 |
| Convertible note payable and accrued interest | $6.779 million | $9.161 million at December 31, 2023 |
| Total liabilities | $18.857 million | $19.048 million at December 31, 2023 |
| Stockholders’ deficit | $15.069 million | $11.733 million at December 31, 2023 |
Operating margin is not meaningful because the Company has no revenue. The Company reported a working capital deficit of approximately $15.5 million and an accumulated deficit of $259.7 million at March 31, 2024.
Material changes versus the prior comparable period
- Net loss decreased by $4.511 million, primarily because operating expenses declined by $3.437 million and the fair-value loss on the convertible note declined by $1.454 million.
- Research and development expense decreased by $1.902 million, principally due to lower clinical trial and development spending.
- General and administrative expense decreased by $1.535 million, driven mainly by lower insurance, stock-based compensation and employee costs, partly offset by higher consulting expense.
- Operating cash burn improved by $2.418 million year over year, although cash declined by $3.276 million during Q1 2024.
- The Company made approximately $2.2 million of cash principal repayments on the Streeterville convertible note and issued shares valued at approximately $0.3 million for additional principal and interest repayment. The note’s remaining principal balance was $5.4 million at March 31, 2024, while its fair value carrying amount was $6.779 million.
- Financing activities provided $0.395 million, including approximately $1.523 million from common-stock and warrant issuances and $1.027 million from a private placement, partially offset by debt repayments.
- All 3.0 million Series A preferred shares were converted into 300,000 common shares during March 2024. Common shares outstanding increased to 9,772,672 at March 31, 2024 from 8,391,940 at December 31, 2023.
Guidance, outlook, commentary and risks
- Going concern: Management stated that substantial doubt exists regarding the Company’s ability to continue as a going concern for at least twelve months from issuance of the financial statements. The Company expects continued losses and negative operating cash flows and plans to seek additional equity, debt, licensing or strategic financing.
- Alvogen agreement: The Company granted Alvogen an exclusive worldwide license for NRX-101 in bipolar depression with suicidality. Alvogen advanced $5 million against the initial milestone under a February 2024 amendment; the remaining $4 million is contingent on a positive FDA end-of-Phase 2 meeting. The advance is subject to repayment if the milestone is not achieved by September 3, 2024. No revenue or milestone had been recognized as of March 31, 2024.
- Clinical and regulatory plans: Management reported positive Phase 2b/3 NRX-101 data, including statistically significant reduction in akathisia, and plans to pursue an NDA with potential accelerated, Breakthrough and Priority Review pathways. Management also expected to transmit ketamine data to the FDA by July 2024 and planned an NDA for HTX-100/NRX-100.
- HOPE Therapeutics: The Company incorporated HOPE and is progressing toward an audit intended to support a proposed spin-off and potential separate Nasdaq listing. The proposed transaction remains subject to financing, regulatory, corporate and other conditions.
- Streeterville dispute: On April 24, 2024, Streeterville alleged an event of default, accelerated outstanding amounts and filed a Utah lawsuit seeking, among other relief, repayment of at least $6.5 million, damages, costs and fees, and restrictions on the proposed HOPE spin-off and additional equity issuance. The filing does not resolve the dispute.
- Subsequent financing: In April 2024, the Company completed a public offering generating approximately $2.0 million of gross proceeds, before approximately $0.3 million of estimated offering costs. It also sold an additional $1.3 million of stock under its ATM program after March 31, 2024.
- Shareholder dilution: The Company issued equity for financing and debt repayments and had 4,034,337 common-stock warrants outstanding at March 31, 2024. A 1-for-10 reverse stock split became effective April 1, 2024, and historical share amounts were retrospectively adjusted.
- Other risks: Key risks include inability to secure financing, debt acceleration, clinical or regulatory failure, dependence on third parties, uncertain commercialization, potential dilution, litigation, intellectual-property obligations and reliance on estimates for fair-value liabilities.
Most important facts for investors to verify
- Whether Streeterville’s alleged default and litigation result in acceleration, an injunction, settlement or additional cash and equity obligations.
- Whether the Alvogen first milestone is achieved and whether the $5 million advance becomes nonrefundable or must be repaid.
- The Company’s post-quarter-end cash balance, ATM issuance activity and remaining debt obligations, including required payments through August 2024.
- Regulatory status and filing timelines for NRX-101 and HTX-100/NRX-100, including whether the FDA accepts or grants the proposed pathways.
- Whether the proposed HOPE spin-off, dividend and separate Nasdaq listing are completed and on what terms.
- Clinical evidence supporting efficacy, safety and the proposed indications, particularly given the limited sample sizes and the non-statistically significant sustained-suicidality result noted for the Phase 2b/3 trial.
- Potential dilution from outstanding warrants, debt conversions, equity offerings and any future financing required to address the going-concern uncertainty.